Bone Biologics has revealed plans for a reverse stock split, consolidating its shares of common stock at a ratio of 1-for-6. This change is scheduled to take effect at 12:01 a.m. ET on Tuesday, June 10. Following the split, the shares will continue to trade on Nasdaq under the current symbol, BBLG, starting at the market open on the same day.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Bone Biologics Corp (BBLG, Financial) is $16.50 with a high estimate of $16.50 and a low estimate of $16.50. The average target implies an upside of 1,943.09% from the current price of $0.81. More detailed estimate data can be found on the Bone Biologics Corp (BBLG) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Bone Biologics Corp's (BBLG, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
